SBIR/STTR Program Status (Jan 14, 2026)

Reauthorization Update: Signs of Movement, but the Freeze Still Hurts

After months of uncertainty following the SBIR/STTR authorization lapse, the last few days have produced two important developments: credible signals that Senate negotiations are active, and fresh evidence that the disruption is now concretely damaging company planning, application pipelines, and agency funding operations.

image created by author using ChatGPT

What changed: Congress is trading proposals

On January 14, 2026, the National Small Business Association (NSBA) indicated that Congress is now exchanging reauthorization proposals, signaling momentum toward a negotiated agreement. They also highlight that the opposing approaches differ on key structural issues, such as whether agencies should have the authority to limit the number of proposals a company can submit annually. Negotiators are still refining and adjusting their positions.

Practical reality: Agencies are still constrained, and applicants feel it directly

Even with movement on negotiations, the operational reality remains that agencies have been treating SBIR/STTR as effectively frozen for new activity. The NIH notice (NOT-OD-26–006) states that NIH SBIR and STTR funding opportunities have expired and that NIH will not issue certain continuation actions until reauthorization.

A January 12 legal analysis aimed at founders and awardees summarizes the immediate effects at NIH in plain terms: new solicitations are closed, active awards can continue, but continuation actions and transitions can be blocked until Congress acts.

The broader innovation community is also elevating the consequences. A January 2026 piece in The Scientist frames the lapse as more than a bureaucratic pause, arguing it threatens the early-stage “non-dilutive” pipeline many biotech and deep-tech companies rely on and explicitly ties the current impasse to unresolved disagreements over what reauthorization should include.

NASA has also publicly stated that, without reauthorization or extension, it cannot issue new solicitations or fund new awards while continuing to administer existing awards.

Where Ernst and Markey are actually diverging

This standoff is still best understood as a disagreement about whether Congress should pass a relatively clean extension first or condition reauthorization on reforms.

Senator Joni Ernst’s (R-IA) position. Ernst has repeatedly emphasized research security, arguing that SBIR/STTR-funded innovation is vulnerable to foreign exploitation and that reforms are needed before she will support a clean extension. Her office has framed the issue in national security terms, including the risk of Chinese espionage and the need for safeguards.

Senator Ed Markey’s (D-MA) position. Markey, as ranking member on the Senate Small Business Committee, has been aligned with passing the House-approved extension bill (H.R. 5100) to restore continuity while debates continue on longer-term reform. The committee’s own posting of Markey’s December 2025 statement describes the ongoing shutdown and highlights the scale and urgency of restoring the programs.

NSBA’s January 14 update explicitly characterizes the current moment as negotiations over proposals from Ernst and Markey, with further changes expected before any final agreement.

Why the last few days matter…

First, SBTC highlighted a newly released National Academies study on the effectiveness of SBIR/STTR programs at DoD (posted January 12, 2026). That does not change the law by itself, but it gives reauthorization advocates fresh, credible ammunition when arguing that the programs work and should be restarted quickly.

Second, the tone of recent coverage has shifted from “will Congress do anything?” to “what compromise text will they land on?” That is not a guarantee of speed, but it is a change in posture that small businesses should notice.

What should small businesses do right now?

If you are actively pursuing SBIR/STTR or managing awards, treat this as an operational risk period rather than a short administrative hiccup. Confirm with each agency program office which items are still moving (reviews, feedback, administrative actions) and which are paused. For NIH-specific planning, read NOT-OD-26–006 carefully and assume delays in any action that depends on renewed program authority.

Three Perspectives Summaries

Neutral: The key update is that Senate negotiations appear real and active, with draft proposals being exchanged, but the functional impact on agencies and applicants continues until reauthorization becomes law.

Devil’s advocate: “Exchanging proposals” can be progress, but it can also be a way to signal movement while still dragging out a fight over reforms. If the political incentives remain aligned to extract concessions, the harm to companies becomes a bargaining chip rather than an urgent problem to solve.

Encouraging: The last week finally produced the kind of concrete indicators you want to see: active negotiation and new external validation (like the National Academies DoD-focused study) that strengthen the case for quickly restarting SBIR/STTR. That combination improves the odds of a workable compromise compared to the stasis of late 2025.

References

• https://www.nsbaadvocate.org/post/news-sbir-sttr-reauthorization-gains-momentum-with-nsba-sbtc-push-as-congress-exchanges-proposals
• https://www.ebhoward.com/as-of-january-2026-where-things-stand-with-sbir-sttr-reauthorization/
• https://grants.nih.gov/grants/guide/notice-files/NOT-OD-26-006.html
• https://www.the-scientist.com/the-federal-government-s-research-innovation-lifeline-has-gone-dark-73913
• https://www.nasa.gov/sbir_sttr/
• https://www.congress.gov/bill/119th-congress/house-bill/5100
• https://sbtc.org/2026/01/
• https://www.jdsupra.com/legalnews/nih-hits-pause-the-sbir-sttr-freeze-4274898/
• https://www.ernst.senate.gov/news/press-releases/democrats-block-ernst-effort-to-safeguard-critical-technology-from-chinese-espionage
• https://www.ernst.senate.gov/news/press-releases/small-businesses-urge-congress-to-pass-ernsts-innovate-act
• https://www.sbc.senate.gov/public/index.cfm/2025/12/ranking-member-markey-statement-on-need-to-reopen-small-business-innovation-programs

Thank you for reading my work. Post comments below if you have any pointers, ideas, suggestions, support, etc.

-Bev

Check out these articles also:

• Why is Trump pushing so hard for Greenland? — https://medium.com/write-a-catalyst/why-is-trump-pushing-so-hard-for-greenland-c844ec1a3bda
• SBIR status from 1/10/26: https://medium.com/sbir-sttr-info/sbir-sttr-program-status-jan-2026-b7e1f885ca62
• My Wife’s book and her profile: https://medium.com/@amburnett
• My Son’s book and his profile: https://medium.com/@cbburnett

You can also ☕buymeacoffee☕ or ☕ko-fi.com☕. Did you know you can clap more than once, up to 50 times! I really like claps 😊🙂.

Thank you for your support!